https://ogma.newcastle.edu.au/vital/access/ /manager/Index en-au 5 Cladribine versus fingolimod, natalizumab and interferon β for multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:36736 Thu 02 Jul 2020 16:31:45 AEST ]]> Higher latitude is significantly associated with an earlier age of disease onset in multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:29942 -23). A reciprocal relationship was seen for ambient ultraviolet radiation (UVR), with a significantly increasing AAO for patients with MS per each quartile increment of ambient UVR (p=1.56×10-17). We found that the AAO of female patients was ~5 months earlier than male patients (p=0.002). AAO of progressive-onset patients with MS were ~9 years later than relapsing-onset patients (p=1.40×10-265). Conclusions: An earlier AAO in higher latitude regions was found in this worldwide European-descent cohort and correlated inversely with variation in latitudinal UVR. These results suggest that environmental factors which act at the population level may significantly influence disease severity characteristics in genetically susceptible populations.]]> Sat 24 Mar 2018 07:31:01 AEDT ]]> Clinical and therapeutic predictors of disease outcomes in AQP4-IgG + neuromyelitis optica spectrum disorder https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:37732 p = 0.001), brainstem onset (HR = 0.45, p = 0.009), azathioprine (HR = 0.46, p <0.001) and mycophenolate mofetil (HR = 0.09, p = 0.012) were associated with a reduced risk of relapse. A greater EDSS was associated with age (β = 0.45 (per decade), p<0.001) and disease duration (β = 0.07 per year, p <0.001). A slower increase in EDSS was associated with azathioprine (β = -0.48, p <0.001), mycophenolate mofetil (β = -0.69, p = 0.04) and rituximab (β = -0.35, p = 0.024). Interpretation: This study has demonstrated that azathioprine and mycophenolate mofetil reduce the risk of relapses and disability progression is modified by azathioprine, mycophenolate mofetil and rituximab. Age and disease duration were the only patient characteristics that modified the risk of relapse and disability in our cohort.]]> Mon 29 Mar 2021 13:09:59 AEDT ]]> Association of Initial Disease-Modifying Therapy with Later Conversion to Secondary Progressive Multiple Sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:48109 Mon 27 Feb 2023 15:22:15 AEDT ]]> Comparative Effectiveness of Autologous Hematopoietic Stem Cell Transplant vs Fingolimod, Natalizumab, and Ocrelizumab in Highly Active Relapsing-Remitting Multiple Sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:50986 Mon 14 Aug 2023 15:59:28 AEST ]]> Defining secondary progressive multiple sclerosis https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:25306 Mon 06 Mar 2023 17:55:37 AEDT ]]> Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score https://ogma.newcastle.edu.au/vital/access/ /manager/Repository/uon:46553 Fri 25 Nov 2022 11:33:34 AEDT ]]>